Pearl River Capital’s Puma Biotechnology PBYI Stock Holding History

Pearl River Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	-$2K	–	664
2018 Q4	$2K	Buy	+100	New	+$3K	0.01%	788

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Pearl River Capital's PBYI Position: Q1 2019 in Review

Pearl River Capital sold out of Puma Biotechnology (PBYI) in Q1 2019, closing a stake of 100 shares — an estimated $2K sold.

Pearl River Capital first reported a position in PBYI in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 158 funds tracked by Wall St. Rank hold PBYI as of Q1 2019.

Pearl River Capital reported no remaining Puma Biotechnology position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 100 Puma Biotechnology shares in Q1 2019, an estimated $2K.
Pearl River Capital first reported a position in Puma Biotechnology in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Puma Biotechnology position peaked at $2K in Q4 2018.
158 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.